Evidence map›Paper›PMID 24716504›Full record

ReviewInternational review of psychiatry (Abingdon, England)2014

Prevalence, mechanisms, and management of cancer-related cognitive impairment.

Michelle C Janelsins, Shelli R Kesler, Tim A Ahles, Gary R Morrow

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International review of psychiatry (Abingdon, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 425 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
425citing papers in PubMed, 15 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06545045 narecruitingnot on this mapstarted 2024, after this paper: background citation

Pilot Testing of Metacognitive Strategy Training to Address Cancer-related Cognitive Impairment in Breast Cancer

TypeinterventionalSponsorUniversity of Missouri-ColumbiaRan2024 to 2026Enrolled50ConditionsBreast Cancer FemaleArmsMetacognitive Strategy Training (MCST), Inactive Control Group
NCT07583979 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

ElectroAcupuncture to Manage Symptoms of Cognitive Toxicity in Cancer Survivors: Assessing impLementation, Cost, and effectIveness for inteGratioN (EAST-ALIGN)

TypeinterventionalSponsorNational Cancer Centre, SingaporeRan2026 to 2029Enrolled168ConditionsCancer-related Cognitive ImpairmentArmsTrue electroacupuncture, Sham electroacupuncture
NCT07729969 narecruitingnot on this mapstarted 2026, after this paper: background citation

Early Cognitive Interventions in Digital Format for Cancer Survivors - INCOTEM

TypeinterventionalSponsorBiogipuzkoa Health Research InstituteRan2026 to 2028Enrolled110ConditionsCognitive Impairment, Cognitive Change, CancerArmsComputerized cognitive treatment, Virtual reality cognitive training
3 · Its place in the literature

Who cites it

425 citing papers in PubMed, 15 syntheses or guidelines pooled it, 731 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

365 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Michelle C JanelsinsDepartment of Surgery, Cancer Control, University of Rochester Medical Center , Rochester, New York , USA.
Shelli R Kesler
Tim A Ahles
Gary R Morrow
Golisano Children's Hospital · USMemorial Sloan Kettering Cancer Center · USStanford University · USUniversity of Rochester Medical Center · US

Funding

UNIVERSITY OF ROCHESTER--CCOP RESEARCH BASEU10CA037420 · NCI · UNIVERSITY OF ROCHESTER · PI MORROW, GARY R · 1985 to 2014
$21.1M
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Multimodal MRI Biomarker of Mild Cognitive Impairment in Breast CancerR01NR014195 · NINR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KESLER, SHELLI R, WEFEL, JEFFREY SCOTT · 2012 to 2017
$2.5M
Clinical and Translational Approaches to Cognitive Impairments in CancerDP2CA195765 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C · 2014 to 2014
$2.3M
Interventions Targeting Inflammation for Chemotherapy-Related Cognitive ProblemsK07CA168886 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C · 2013 to 2017
$724k
NCI NIH HHS DP2 CA195765NCI NIH HHS K07 CA168886NCI NIH HHS K07CA168886NCI NIH HHS R01 CA172145NCI NIH HHS U10 CA037420NINR NIH HHS R01 NR014195
6 · The paper itself

Abstract

This review summarizes the current literature on cancer-related cognitive impairment (CRCI) with a focus on prevalence, mechanisms, and possible interventions for CRCI in those who receive adjuvant chemotherapy for non-central nervous system tumours and is primarily focused on breast cancer. CRCI is characterized as deficits in areas of cognition including memory, attention, concentration, and executive function. Development of CRCI can impair quality of life and impact treatment decisions. CRCI is highly prevalent; these problems can be detected in up to 30% of patients prior to chemotherapy, up to 75% of patients report some form of CRCI during treatment, and CRCI is still present in up to 35% of patients many years following completion of treatment. While the trajectory of CRCI is becoming better understood, the mechanisms underlying the development of CRCI are still obscure; however, host characteristics, immune dysfunction, neural toxicity, and genetics may play key roles in the development and trajectory of CRCI. Intervention research is limited, though strategies to maintain function are being studied with promising preliminary findings. This review highlights key research being conducted in these areas, both in patient populations and in animals, which will ultimately result in better understanding and effective treatments for CRCI.

Indexed as

Cognition DisordersAnimalsBreast NeoplasmsFemaleHumans

Identifiers

PMID24716504
PMCPMC4084673
OpenAlexW2098192159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.